Added to YB: 2026-05-26
Pitch date: 2026-05-22
GSK [neutral]
GSK plc
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 76.4B
Pitch Price
N/A
Price Target
N/A
Dividend
3.76%
EV/EBITDA
7.88
P/E
13.49
EV/Sales
2.80
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 22/5/2026 - GSK – Arexvy approval
GSK (update): Japan expanded Arexvy (RSV vaccine) approval to adults 18-59 at increased risk + all 60+, potentially adding millions to addressable market (42M aged 18-49 in Japan). Take-up uncertain but expands commercial opportunity. Trading 9.9x 2027 consensus EPS, 3.9% yield.
Read full article (1 min)